Evidence map›Paper›PMID 41673408›Full record

ArticleScientific reports2026

Urinary CD4

Viona Laas, Frederic Christian Feindt, Pascal Böse, Tom Zimmermann, Pavels Klimicevs, Julia Hagenstein, Laura-Isabell Ehnold, Georg R Herrnstadt, Matthias T Warkotsch, Hans-Joachim Paust and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Viona Laas *III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Frederic Christian Feindt *III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Pascal BöseIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Tom ZimmermannDepartment of Pathology, Section of Nephropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Pavels KlimicevsIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Julia HagensteinIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Laura-Isabell EhnoldIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Georg R HerrnstadtIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Matthias T WarkotschIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Hans-Joachim PaustIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Ulf PanzerIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Christian F KrebsIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Tobias B HuberIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Thorsten WiechDepartment of Pathology, Section of Nephropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Oliver M SteinmetzIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Simon MelderisIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. s.melderis@uke.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sjögren's Disease (SjD) is the most common connective tissue disease. An estimated 5-27% of patients have kidney involvement, usually in the form of tubulointerstitial nephritis (TIN). To date, there are no validated biomarkers for either diagnosis or assessment of therapeutic response. Since one of the hallmarks of TIN is leukocyturia, we aimed at investigating the potential role of urinary leukocytes as a diagnostic tool for SjD-TIN. We prospectively recruited 13 patients with SjD, that underwent kidney biopsy for suspected TIN. A multicolor flow cytometry panel was established to quantify 8 different urinary leukocyte populations. Our analyses showed, that urinary CD4

Indexed as

CD4-Positive T-LymphocytesNephritis, InterstitialSjogren's SyndromeT-Lymphocytes, Helper-InducerAdultAgedBiomarkersFemaleFlow CytometryHumansMaleMiddle AgedProspective StudiesBiomarkers

Identifiers

PMID41673408
PMCPMC12894895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.